News Release

Translation

June 27, 2018
JCR Pharmaceuticals Co., Ltd.

Notice of Personnel Change

JCR Pharmaceuticals Co., Ltd. (TSE 4552: Chairman and President Shin Ashida, “JCR”) announced today that the personnel change as below.

(As of June 27, 2018)

Name	New Title	Current title
Hiroyuki Sonoda Ph.D.	Corporate Officer Executive Director, Research Planning Division	Executive Director, Research Planning Division

(Career)

Apr. 2003	Joined JCR Pharmaceuticals Co., Ltd.
	Advanced Medical Technology Research and Development Center
Oct. 2008	Scientist (Chief), Research Institute, Research and Development Division
Oct. 2012	Associate Senior Scientist (Assistant Manager),
	Research Institute, Research Division
Oct. 2014	Senior Scientist (Manager),
	Biopharmaceutical Innovation Research Department,
	Research Institute, Research Division
Apr. 2015	Senior Scientist (Manager),
	Biopharmaceutical Innovation Research Department,
	Research Institute, Research Division
	Manager, Business Development Department
Apr. 2016	Director (Research Team), Corporate Planning Division
	Group Manager, Advanced Biotechnology II,
	Biopharmaceutical Innovation Research Institute, Research Division
Oct. 2017	Unit Leader, Frontier Research Unit
	Director (Research Team), Corporate Planning Division
	Group Manager, Advanced Biotechnology II,
	Biopharmaceutical Innovation Research Institute, Research Division
Apr. 2018	Executive Director, Research Planning Division

(As of July 1, 2018)

Name	New Title	Current title
Atsuko Sato	Corporate Officer Executive Director, Quality Assurance Division Director, Regulatory Affairs Dept.	—
(Career)		
Apr. 1983	Joined Pfizer Taito Co., Ltd. (currently, Pfizer Japan Inc.)	
Mar. 1989	Joined SmithKline Beecham Pharmaceuticals (currently, GlaxoSmithKline K.K.)	
Aug. 2001	Joined Banyu Pharmaceutical Co., Ltd. (currently, MSD K.K.)	
Feb. 2009	Joined Novartis K.K.	
Oct. 2012	Joined Amgen Development K.K. (currently, Amgen Astellas BioPharma K.K.)	
Yoshihiko Ohnishi	Corporate Officer Executive Director, Sales Division Director, Tokyo Metropolitan Area Sales Dept.	Corporate Officer Executive Director, Sales Division
Kazuhiro Kobayashi	Director, Marketing Dept. Sales Division	Associate Director, Marketing Dept. Sales Division
Yoshihiro Kaneko	Director, Sales Operations Administration Dept. Sales Division	Director, Tokyo Metropolitan Area Sales Dept.
Masaru Somatomo	Director, Office of Audit & Supervisory Board Members Director, Internal Audit Dept.	Director, Office of Audit & Supervisory Board Members

(Reference) Members of Corporate Officers on July 1, 2018

Akihiro Haguchi	Executive Director, Administration Division
Takayo Egawa	Director, Overseas Business Promotion
Tohru Hirato, D.V.M.	Executive Director, Research Division
Yoshihiko Ohnishi	Executive Director, Sales Division Director, Tokyo Metropolitan Area Sales Dept.
Yutaka Honda	Executive Director, Corporate Planning Division
Hiroyuki Sonoda Ph.D. (new)	Executive Director, Research Planning Division
Atsuko Sato (new)	Executive Director, Quality Assurance Division Director, Regulatory Affairs Dept.

[About JCR Pharmaceuticals]

JCR is a specialty pharma engaged in the research, development, manufacture and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, “Contributing towards people’s healthcare through pharmaceutical products” drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient community.

[Cautionary Statement Regarding Forward-Looking Statements]

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights , an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jcrpharm.co.jp

END

###